Business
Jazz Pharmaceuticals to Report 2022 First Quarter Financial Results on May 4, 2022
DUBLIN, April 20, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 first quarter financial results on
About this update from Jazz Pharmaceuticals Plc
[{"type":"text","content":"DUBLIN, April 20, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 first quarter financial results on Wednesday, May 4, 2022, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2022 first quarter financial results and provide a business and financial update. \nAudio webcast/conference call:U.S. Dial-In Number: +1 855 353 7924International Dial-In Number: +1 503 343 6056Passcode: 7492554\nA replay of the conference call will be available through May 11, 2022.\nReplay U.S. Dial-In Number: +1 855 859 2056Replay International Dial-In Number: +1 404 537 3406Passcode: 7492554\nInterested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. \nAbout Jazz PharmaceuticalsJazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases – often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.\nInvestors: Andrea N. Flynn, Ph.D.Vice President, Head, Investor RelationsJazz Pharmaceuticals [email protected] +353 1 634 3211U.S. +1 650 496 2717\nMedia Contact:Kristin BhavnaniHead of Global Corporate CommunicationsJazz Pharmaceuticals [email protected] +353 1 637 2141U.S. +1 215 867 4948\n\n\n\n\n View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-2022-first-quarter-financial-results-on-may-4-2022-301529402.html\nSOURCE Jazz Pharmaceuticals plc","length":4834,"tagName":"div"}]